Introducing the MYMR Prostate Tracker

18 August 2023

The MYMR (My Medical Record) project is a digital All-Wales development in which Velindre University NHS Trust is participating.

It is a really positive development which will enable patients with a Prostate Cancer diagnosis and stable disease to self-manage and to make contact through the system with a relevant health care professional, if they have support and information queries.

Through My Medical Record, patients will have remote access to their PSA result, which will provide a pivotal role in developing and implementing a new way of providing follow up care of patients living with Prostate Cancer.

Currently, patients living with Prostate Cancer have been followed up at regular intervals by their healthcare teams either face-to-face, by telephone or by letter follow-up.

This system will be run by the Urology Cancer Support Worker who provides the initial introduction including registration, coordinates the appropriate follow up blood appointments, sends the blood form to the patient and offers a Holistic Need Assessment (HNA). The Cancer Support Worker will then monitor the PSA result and take appropriate action if required based on a protocol.

The Cancer Support Worker will play a pivotal role in supporting the patient pathway for the patients on the self-management follow-up by being a point of contact for the patient through the system using education resources, advice, signpost to other resources of support and escalating any complex cases to the Clinical Nurse Specialist.

We are introducing the first patients to MYMR in August.

Functions available on MYMR

Benefits to using MYMR – Prostate Tracker

• Patient empowerment/self-management
• Reduce waiting times for Blood test results
• Increased Patient Access to Clinical information
• Improved communications between Urology Team and Patient
• Reduce the need for hospital appointments – better use of Clinical Nurse Specialist Time
• Improved patient education in relation to potential treatment side effects and ongoing cancer management